15 September 2022  
EMA/CHMP/722554/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Veklury 
remdesivir 
On 15 September 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Veklury. The marketing authorisation holder for this medicinal product is Gilead Sciences Ireland UC. 
The CHMP adopted an extension to the existing indication for Veklury to include the treatment of 
paediatric patients from the age of 4 weeks.   
For information, the full indication for Veklury will be as follows:2 
Veklury is indicated for the treatment of coronavirus disease 2019 (COVID-19) in: 
•  Adults and paediatric patients adolescents(aged 12 to less than 18 years at least 4 weeks of 
age and weighing at least  3 kg) with pneumonia requiring supplemental oxygen (low- or high flow 
oxygen or other non-invasive ventilation at start of treatment) 
•  Adults  and  paediatric  patients  (weighing  at  least  40kg)  who  do  not  require  supplemental 
oxygen and who are at increased risk of progressing to severe COVID-19 
(see section 5.1) 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR) and will be available in all official European Union languages after a decision on this change to the 
marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
